Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference
Cognition Therapeutics Is Targeting A Critical Form Of Dementia Cognition Therapeutics Is Targeting A Critical Form Of Dementia
Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday? Cognition Therapeutics' CT1812 improves dementia with Lewy bodies outcomes, reducing anxiety, hallucinations, and functional decline in trials.
November’s Small-Cap Treasures: 3 Stocks Poised for Growth Three promising small-cap stocks, poised for growth in healthcare, cybersecurity, and renewable energy, offer compelling investment opportunities for November.
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q2 2024 CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning!
Tivic Health Systems (TIVC) Stock Pops Another 39% Tivic Health Systems stock is up on Monday with heavy trading of TIVC shares as recent volatility continues for the company's units.
Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study Cognition Therapeutics' Phase 2 'SHINE' study shows CT1812 leads to cognitive improvement in Alzheimer's patients over six months. Participants showed better performance on cognitive and functional measures compared to placebo.
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today? NLS Pharmaceutics stock is up on Monday after the company provided NLSP investors with details on a merger deal with Kadimastem.
Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today? Cognition Therapeutics stock is down on Monday after CGTX investors read the latest data from a Phase 2 clinical trial report.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024 CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023 CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Earnings Scheduled For March 26, 2024 Companies Reporting Before The Bell • bluebird bio (
NASDAQ:BLUE ) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
